Omni Bio Pharmaceutical, Inc. is a development-stage biotechnology company focused on the research, development and commercialization of novel therapeutic compounds for pain management and inflammatory conditions. The company’s lead platform is built around proprietary poloxamer-based polymers designed to stabilize cell membranes and reduce tissue damage. Omni Bio’s pipeline targets acute and chronic pain syndromes, including sickle cell disease pain crises, musculoskeletal injuries and neuropathic pain, with the goal of delivering safer, non-opioid alternatives to current treatments.
The company’s flagship product candidate, P188 NF, is a pharmaceutically pure formulation of poloxamer 188 that has received regulatory clearance for clinical investigation. In preclinical and early clinical studies, P188 NF has demonstrated the potential to mitigate cell membrane leakage and attenuate inflammatory responses, supporting its development as both an acute rescue therapy and a longer-term adjunctive treatment. Omni Bio continues to explore additional indications for its membrane-repair technology, including cardiac and pulmonary injury applications, through strategic partnerships and investigator-initiated trials.
Founded in the mid-1990s, Omni Bio Pharmaceutical is headquartered in Red Bank, New Jersey, and serves markets throughout North America while maintaining collaborative research agreements with academic centers and contract organizations in Europe and Asia. The company’s management team brings extensive experience in pharmaceutical development, clinical operations and regulatory affairs. Under the leadership of its senior executives, Omni Bio is advancing its pipeline assets toward key clinical milestones and pursuing out-licensing and co-development opportunities to maximize the therapeutic and commercial potential of its technology platform.
AI Generated. May Contain Errors.
